Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Takeda’s Uloric Gets CV Death Warning And Restricted Indication, But No REMS

Feb 24 2019

• By Sue Sutter

Wood chopping with hand axe

Related Content

Is There A REMS In Uloric’s Future? US FDA Panelists Say Yes, Agency Says Not Likely

Jan 12 2019

Ironwood Pulls Plug On Struggling Gout Drug Zurampic

Aug 06 2018

Janssen’s Esketamine Needs Better Defined REMS, US FDA Panel Says

Feb 13 2019

US FDA’s REMS Reluctance On Display At Recent Advisory Committees

Jan 25 2019

Can A REMS Mitigate CV Risks? Avandia, Meridia Offer Point, Counterpoint

Jan 15 2019

Takeda’s Uloric: CV Mortality Signal Leads US FDA To Ponder Regulatory Options

Jan 10 2019

Related Companies

Takeda Pharmaceutical Co. Ltd.

Amgen, Inc.

UCB S.A.

Sanofi

Lexicon Pharmaceuticals, Inc.

Johnson & Johnson

Ironwood Pharmaceuticals, Inc.

Additional Topics

United States Drug Safety Post Market Regulation & Studies Regulation Inflammation BioPharmaceutical

More from Drug Safety

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window